Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum COSCIENS Biopharma Inc T.AEZS

COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of unmet medical need. Its lead product, macimorelin (Macrilen; Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone... see more

TSX:AEZS - Post Discussion

COSCIENS Biopharma Inc > Avenanthramide in combination with colchicine
View:
Post by prophetoffactz on Jun 09, 2024 12:47pm

Avenanthramide in combination with colchicine

Yes, colchicine and avenanthramides (AVA) reduce inflammation through independent mechanisms, and combining them is likely to enhance the reduction of inflammation in treating heart disease and other inflammatory conditions.

Colchicine Mechanism

Colchicine inhibits the formation of microtubules, which are essential for many cellular functions including cell division and migration. This disrupts the inflammatory response by:
  • Reducing the activity of the NLRP3 inflammasome, which decreases production of pro-inflammatory cytokines like IL-1β, IL-18, and IL-6.
  • Preventing the migration of neutrophils and other immune cells to sites of inflammation.

Avenanthramide Mechanism

Avenanthramides inhibit the NF-κB signaling pathway, which regulates the expression of inflammatory genes. This leads to:
  • Decreased production of pro-inflammatory cytokines like TNF-α, IL-6, and chemokines.
  • Reduced expression of cell adhesion molecules that recruit immune cells.
Since colchicine and avenanthramides act through different mechanisms to inhibit distinct aspects of the inflammatory response, their combined use could provide an enhanced anti-inflammatory effect. This synergistic approach may be beneficial in treating inflammatory conditions like heart disease, where reducing inflammation is a key therapeutic goal.
Be the first to comment on this post